Background: Gene Expression

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

Advances and Emerging Therapy for Lung Cancer

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)

One good example of considering gene expressions at the review for approval Taxol: Indicated for the adjuvant treatment of node- positive breast cancer.

Phase II Design Strategies Sally Hunsberger Ovarian Cancer Clinical Trials Planning Meeting May 29, 2009.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Educational Objectives Metastatic Breast Cancer: Scope of the Problem.

Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.

T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.

1 BLA Sipuleucel-T (APC-8015) FDA Statistical Review and Findings Bo-Guang Zhen, PhD Statistical Reviewer, OBE, CBER March 29, 2007 Cellular, Tissue.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term.

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

R2 김재민 / Prof. 정재헌 Journal conference 1.

Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

ECCO ESMO 2011 GI Cancer Updates “VELOUR” Study

Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.

Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL

Schema of the NSABP B-34 trial evaluating adjuvant oral clodronate in patients with resected stage I and II operable breast cancer (Chemo, adjuvant chemotherapy;

Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.

Treatment allocation bias

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Swain SM et al. Proc SABCS 2012;Abstract P

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Information for participating Sites

Activity Goals. Activity Goals Discussion Topics.

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.

Volume 69, Issue 5, Pages (May 2016)

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Volume 69, Issue 4, Pages (April 2016)

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in stage II and III.

MJ O’Connell for the ACCENT Collaborative Group

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Mohamed L. Sorror, MD, MSc ASH Oral presentation December 2018

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Volume 24, Issue 8, Pages (August 2016)

Empiric versus Site-Directed Chemotherapy in Cancer of Unknown Primary

Overall Survival and Progression-free Survival

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

Background: Gene Expression Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

Methods: Phase II Trial Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

Methods: Gene Expression Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

CHT Slide 9 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

Slide 10 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

Slide 11 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

Slide 12 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

Slide 13 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

Slide 15 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

Conclusions: Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

Slide 18 Presented By Arlene Siefker-Radtke at 2015 Genitourinary Cancers Symposium

Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium Comparative effectiveness of adjuvant chemotherapy versus observation in patients with ≥ pT3 and/or pN+ bladder cancer Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Randomized Trials of Adjuvant Therapy Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium Study Overview Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium Methods - I Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium Methods - II Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium Study Cohort Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Variables associated with treatment selection Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Effect of adjuvant chemotherapy on hazard ratio for overall survival Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Impact of adjuvant chemotherapy on overall survival in patient subsets Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Analyses of adjuvant chemotherapy Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium

Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium Conclusions Presented By Matt Galsky at 2015 Genitourinary Cancers Symposium